Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Exp Neurol. 2015 Dec 11;277:1–9. doi: 10.1016/j.expneurol.2015.12.003

FIGURE 7. Bexarotene treatment causes body-weight loss, hepatomegaly and liver dysfunction in aged mice.

FIGURE 7

A. Body weight of the aged control and nLrp1−/− mice (male, 20-24 months) with or without bexarotene treatment (100 mg/kg/day) was monitored at least once a week throughout the treatment period. Body weight change of each mouse was calculated by ratio to the initial body weight at the beginning of the treatment. Data are plotted as mean ± SEM (N=7-10/group). B. Liver weight of the mice was measured at the end of treatment, and normalized by the initial body weight for each mouse (N=7-10/group). **p<0.01 by Tukey’s post-hoc analysis after two-way ANOVA. C-E. The levels of alanine transaminase (ALT) (C), total cholesterol (D) and triglyceride (E) were measured in plasma from the mice (N=9-11/group). Black and red dots indicate control and nLRP1−/− mice, respectively. Data are plotted as mean ± SD. **p<0.01 by Student’s t-test.